Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience AB: Interim report January–March 2022
A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...
Invitation to the Presentation of Alligator Bioscience´s Interim Report January – March 2022 on April 27, 2022
LUND (Sweden) – April 22, 2022 – Alligator Bioscience will host a conference call (in English) for investors, analysts and media on Wednesda ...
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
Lund, Sweden, April 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for th ...
Change in number of shares and votes in Alligator Bioscience AB
During the month of March, the number of shares and votes in Alligator Bioscience AB have increased due to directed issue and repurchase of ...
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
Lund, Sweden, March 23, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical P ...
Issue and repurchase of series C shares for performance-based share saving program
Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...
Alligator Bioscience publishes Annual Report for 2021
Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been publi ...